Rightsy — Protect your rights: IP search and flat-fee legal services

Search trademarks

Sanofi-Aventis v. Day Corporation

WIPO Case No. D2004-1075

Outcome
Transfer
Domain names
endotelon.biz, endotelon.com, endotelon.info, endotelon.net, endotelon.org
Complainant
Sanofi-Aventis (France)
Complainant's counsel
Bird & Bird Solicitors
Respondent
Day Corporation (Nevada)
Panelist
Nicoletta Colombo
Registrar
iHoldings.com Inc. d/b/a DotRegistrar.com
Decided
25 Mar 2005
Language
English

Source: WIPO Arbitration and Mediation Center. Official copy: https://www.wipo.int/amc/en/domains/decisions/html/2004/d2004-1075.html

WIPO Arbitration

and Mediation Center

ADMINISTRATIVE

PANEL DECISION

Sanofi-Aventis v. Day Corporation

Case No. D2004-1075

1. The Parties

The Complainant is Sanofi-Aventis, of Paris, France, represented by Bird & Bird Solicitors, France.

The Respondent is Day Corporation, C/O Chaille Garcia, Carson City, Nevada

United States of America.

2. The Domain Names and Registrar

The disputed domain names <endotelon.biz>, <endotelon.com>,

<endotelon.info>, <endotelon.net> and <endotelon.org> are

registered with iHoldings.com Inc. d/b/a DotRegistrar.com.

3. Procedural History

The Complaint was filed with the WIPO Arbitration and Mediation Center (the “Center”) on December 20, 2004. On December 20, 2004, the Center transmitted by email to iHoldings.com Inc. d/b/a DotRegistrar.com a request for registrar verification in connection with the domain names at issue. On December 20, 2004, iHoldings.com Inc. d/b/a DotRegistrar.com transmitted by email to the Center its verification response confirming that the Respondent is listed as the registrant and providing the contact details for the administrative, billing, and technical contact. The Center verified that the Complaint satisfied the formal requirements of the Uniform Domain Name Dispute Resolution Policy (the “Policy”), the Rules for Uniform Domain Name Dispute Resolution Policy (the “Rules”), and the WIPO Supplemental Rules for Uniform Domain Name Dispute Resolution Policy (the “Supplemental Rules”).

In accordance with the Rules, paragraphs 2(a) and 4(a), the Center formally notified the Respondent of the Complaint, and the proceedings commenced on December 29, 2004. In accordance with the Rules, paragraph 5(a), the due date for Response was January 18, 2005. The Response was filed with the Center on January 9, 2005.

The Center appointed Nicoletta Colombo as the sole panelist in this matter on March 15, 2005. The Panel finds that it was properly constituted. The Panel has submitted the Statement of Acceptance and Declaration of Impartiality and Independence, as required by the Center to ensure compliance with the Rules, paragraph 7.

In the light of the tenor of Response from the Respondent,

which states willingness to cooperate with the transfer of the contested domain

names, the Center asked the Complainant to confirm whether the proceeding should

be suspended to reach a settlement. The Complainant on January 14, 2005, confirmed

its wish to suspend for 15 days the proceedings. On February 1, 2005, the Complainant

asked an additional one month period of suspension because the parties were

trying to find an agreement. On March 4, 2005, the Complainant asked to re-institute

the proceedings and the Center on the same day informed the Respondent that

the proceedings had been re-instituted.

4. Factual Background

The Complainant is one of the world’s top 20 pharmaceutical groups, founded in 1973 and merged with Synthelabo on May 1999, creating the second largest pharmaceutical company in France. The Complainant products are distributed in the United States of America through a number of channels and in particular through a website. Enotelon is a well –known drug produced by the Complainant since 1978 to cure chronic venous insufficiency. The Complainant has filed trademark applications for Endotelon in more that 100 countries.

The Respondent Day Corporation registered <endotelon.com> on December 31, 2002,

<endotelon.info>, <endotelon.net> and

<endotelon.org> on April 25, 2003, and <endotelon.biz> on April 25, 2004.

The disputed domain names lead to a website which presents the Respondent product

“Flavay” similar to Endotelon but better under many circumstances

according to the Respondent.

5. Parties’ Contentions

A. Complainant

Complainants contend the following :

1) That the disputed domain names <endotelon.biz>, <endotelon.com>, <endotelon.info>, <endotelon.net> and <endotelon.org> are confusingly similar to trademarks in which Complainant has rights.

2) That the Respondent has no rights or legitimate interests in respect of the disputed domain names, that it is not commonly known by the disputed domain names and that it is not making any legitimate or fair use of the disputed domain names.

3) That Complainant has never licensed or otherwise authorized the Respondent to use its trademarks or to use them as part of the disputed domain names.

4) That the Respondent registered the disputed domain names in bad faith, knowing that ENDOTELON corresponds to a trademark as results clearly from the website run “endotelon.com” where it is explained what is “Endotelon” and where “Endotelon” is presented as a trademark with the sign “TM”.

5) The bath faith of the Respondent is also demonstrated by the fact that the disputed domain names lead to a website “www.opcs.com” which denigrates Endotelon product for the benefit of a product called “Flavay” which is supposed to get the same effects that Endotelon but in a safer way.

B. Respondent

The Respondent replied that it does not oppose the transfer of the contested domain names to Sanofi-Aventis.

About allegations and statements of the Complainant,

the Respondent maintains that its predecessor registered the domain names in

good faith because even if aware that Endotelon, it was unaware that the Complainant

wanted to sell Endotelon product in USA. Day Corporation has never denigrated

Endotelon; the purpose of the web pages associated to the Respondent website

were purely to educate American consumers about the French origin of oligomeric

proanthocyanidins and Day Corporation has stopped its plan in using the trademark

Endotelon for its business.

6. Discussion and Findings

The Respondent, even if it tried to explain the reason

of the registration of the contested domain names, did not oppose to the transfer

of the disputed domain names to the Complainant. Several prior decisions in

which the Respondent has consented to transfer the contested domain names conclude

that the requirements of Paragraph 4 of the Policy are fulfilled (see eMusic.com,

Inc. v. Mp3DownLoadCity, WIPO Case No. D2004-0967,

Lonely Planet Publications Pty Ltd. v. Hoang Anh Minh and cicvn.com, WIPO

Case No. D2003-0355, Desotec N.V. v. Jacobi Carbons Ab, WIPO

Case No. D2000-1398. Therefore, considering this consent to a transfer of

the domain names and other facts of the case, this Administrative Panel concludes

that the requirements of Paragraph 4 of the Policy are fulfill.

7. Decision

For all the foregoing reasons, in accordance with Paragraphs 4(i) of the Policy and 15 of the Rules, the Panel orders that the domain names, <endotelon.biz>, <endotelon.com>, <endotelon.info>, <endotelon.net> and <endotelon.org> be transferred to the Complainant.

Nicoletta Colombo

Sole Panelist

Date: March 25, 2005

More cases by this complainant

Open this decision on Rightsy